Go Deep
Alivus Life Sciences Limited
Alivus Life Sciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 22,967 | 27.4 | 4.96 | 0.02 | 1,345.50 |
| Sep 2026 | 22,967 | 27.4 | 4.96 | 0.02 | 1,345.50 |
| Sep 2026 | 22,967 | 27.4 | 4.96 | 0.02 | 1,345.50 |
| Oct 2026 | 22,639 | 28.0 | 5.06 | 0.02 | 1,374.20 |
| Oct 2026 | 22,059 | 27.1 | 4.89 | 0.02 | 1,326.30 |
Alivus Life Sciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 6,404,140,000.0 | 6,891,170,000.0 | 6,728,890,000.0 | 6,018,460,000.0 |
| Net Profit | 1,600,760,000.0 | 1,626,610,000.0 | 1,502,610,000.0 | 1,215,350,000.0 |
| EPS | 13.0 | 13.2 | 12.2 | 9.9 |
Alivus Life Sciences Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 25,041,940,000.0 | 23,398,350,000.0 | 21,847,700,000.0 | 20,478,400,000.0 | — |
| Net Profit | 5,644,830,000.0 | 4,856,270,000.0 | 4,708,880,000.0 | 4,669,610,000.0 | — |
| EPS | 46.0 | 39.6 | 38.4 | 38.1 | — |
Alivus Life Sciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 39,828,970,000.0 | 34,114,530,000.0 | 28,504,120,000.0 | 27,021,470,000.0 | — |
| Total Liabilities | 6,507,650,000.0 | 5,940,810,000.0 | 5,180,900,000.0 | 5,639,400,000.0 | — |
| Total Equity | 33,321,320,000.0 | 28,173,720,000.0 | 23,323,220,000.0 | 21,382,070,000.0 | — |
Owes vs Owns
Alivus Life Sciences Limited owed ₹0.16 for every ₹1 it owned in Mar 2026, down from ₹0.21 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.16× | 0.17× | 0.18× | 0.21× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Alivus Life Sciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 19.6%Receivables 26.9%Inventory 17.4%Fixed assets (tangible) 32.6%Intangible assets 0.8%Other assets 2.7%
How it's funded — Mar 2026
Long-term debt 1.2%Payables 9.3%Other liabilities 5.6%Shareholders' equity 83.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 782.4 | 548.7 | 301.4 | 283.8 |
| Receivables | 1,073.0 | 969.7 | 765.4 | 806.8 |
| Inventory | 691.9 | 673.9 | 666.6 | 604.2 |
| Fixed assets (tangible) | 1,296.8 | 1,045.7 | 904.8 | 825.5 |
| Intangible assets | 29.9 | 19.9 | 14.9 | 18.0 |
| Long-term investments | 0.1 | 0.1 | 0.1 | 0.1 |
| Other assets | 108.8 | 153.4 | 197.3 | 163.8 |
| Liabilities & equity | ||||
| Short-term debt | 8.0 | 5.6 | 2.4 | 2.3 |
| Long-term debt | 48.8 | 51.0 | 14.8 | 17.1 |
| Payables | 372.4 | 390.5 | 368.7 | 427.2 |
| Other liabilities | 221.6 | 147.0 | 132.3 | 117.4 |
| Shareholders' equity | 3,332.1 | 2,817.4 | 2,332.3 | 2,138.2 |
| Net tangible assets | 3,302.2 | 2,797.4 | 2,317.5 | 2,120.2 |
Alivus Life Sciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 5,654,130,000.0 | 3,915,240,000.0 | 4,135,150,000.0 | 3,060,060,000.0 | — |
| Investing Activities | -5,701,530,000.0 | -6,156,450,000.0 | -1,164,830,000.0 | -1,467,470,000.0 | — |
| Financing Activities | -643,400,000.0 | -62,310,000.0 | -2,794,410,000.0 | -3,875,930,000.0 | — |